Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01393964 · ClinicalTrials.gov registry record · Phase 1
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01393964 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 35 participants.
The verdict
NCT01393964, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the concentration of Elotuzumab in Myeloma patients with very low kidney function including patients on dialysis.
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- BIOLOGICAL Elotuzumab (BMS-901608; HuLuc63)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2012-01-06 |
| Est. Completion | 2016-07-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01393964
The ClinicalTrials.gov registry entry for NCT01393964 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT01393964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01393964 about?
NCT01393964 is a clinical study titled "Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function". The purpose of the study is to assess the concentration of Elotuzumab in Myeloma patients with very low kidney function including patients on dialysis.
What is the current status of trial NCT01393964?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2012-01-06. Estimated completion is 2016-07-18.
What interventions are being tested in trial NCT01393964?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Elotuzumab (BMS-901608; HuLuc63) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01393964?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.